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Congenital deafness affects about 1 in 1000 children and more than half of them
have a genetic background such as Connexin26 (CX26) gene mutation. Inner ear cell
therapy for sensorineural hearing loss has been expected to be an effective therapy for
hereditary deafness. Previously, we developed a novel strategy for inner ear cell therapy
using bone marrow mesenchymal stem cells as a supplement for cochlear fibrocytes
functioning for cochlear ion transport. For cell therapy targeting hereditary deafness,
a more effective cell delivery system to induce the stem cells into cochlear tissue is
required, because gene mutations affect all cochlear cells cochlear cells expressing genes
such as GJB2 encoding CX26. Stem cell homing is one of the crucial mechanisms to
be activated for efficient cell delivery to the cochlear tissue. In our study, monocyte
chemotactic protein-1, stromal cell-derived factor-1 and their receptors were found to
be a key regulator for stem cell recruitment to the cochlear tissue. Thus, the activation
of stem cell homing may be an efficient strategy for hearing recovery in hereditary
deafness.
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HEREDITARY DEAFNESS AND THE MOUSE MODELS
ASSOCIATED WITH IONIC HOMEOSTASIS IN COCHLEA
Approximately one in 1,000 children is affected by severe hear-
ing loss at birth or during early childhood, which is defined
as pre-lingual deafness (Morton, 1991; Petersen and Willems,
2006) with about half of the cases attributable to genetic causes
(Birkenhager et al., 2010). Among >100 known forms of non-
syndromic deafness with identified genetic loci, by far the most
common and best characterized is the one associated with GJB2
(OMIM 121011), the gene encoding the connexin26 (CX26)
protein (Kelsell et al., 1997). Recently we demonstrated that a
mutation in CX26 induces macromolecular degradation of large
gap junction plaque (GJP) complexes by using a CX26 dom-
inant negative transgenic (Inoshita et al., 2014) and deficient
mouse model (Kamiya et al., 2014). This molecular pathogen-
esis called “GJP disruption” is thought to be associated with
a decreased endocochlear potential (EP) generated by cochlear
ion transport. GJP disruption was also found in a mouse
model for deafness type 3 (DFN3), which is the most com-
mon type of in X chromosome–linked, non-syndromic hearing
loss. This mouse model has a deficiency of transcription factor
Brn4 encoded by POU domain, class 3, transcription factor 4
(POU3F4; Kidokoro et al., 2014). We reported that the low EP
observed in this mouse appeared to be caused by GJP disrup-
tion. A mouse model with a mutation in BSND, which encodes
barttin, shows Bartter syndrome type IV, a hearing impair-
ment (Nomura et al., 2013) also thought to be caused by a
low EP.
INNER EAR CELL THERAPY TARGETING COCHLEAR
FIBROCYTE
Previously, we demonstrated that local inflammation at the lateral
wall promotes the invasion of transplanted mesenchymal stem
cells (MSCs) to the lateral wall (Kamiya et al., 2007). In our
microarray analysis with cochlear mRNA after 3-nitropropionic
acid (3-NP) administration, we showed the up-regulation of
chemokine MCP-1 (monocyte chemotactic protein-1) which is
known to be a stem cell homing factor (Belema-Bedada et al.,
2008). Thus, the invasion of MSCs shown in our previous study
was thought to be enhanced by stem cell homing factors.
STEM CELL HOMING
Stem cell homing is one the crucial mechanisms to be activated for
efficient cell delivery to the cochlear tissue. Belema-Bedada et al.
(2008) demonstrated that efficient homing of multipotent adult
MSCs into hearts damaged by ischemia/reperfusion was depen-
dent on FROUNT-Mediated clustering of chemokine (C-C motif)
receptor 2 (CCR2). They showed that the cytokine receptor CCR2
is necessary for organ-specific homing of pluripotent adult MSCs
and that these cells are recruited by the CCR2 ligand MCP-
1/CCL2 and express stromal cell-derived factor 1 (SDF-1), which
might trap additional bone marrow-derived circulating cells to
contribute to the complex process of homing and retention of
circulating stem and progenitor cells to remodel diseased organs.
As for homing to cochlea, Tan et al. (2008) demonstrated the
homing capability of bone marrow-derived cells to a deafened
cochlea. They suggested that the upregulation of SDF-1 in the
www.frontiersin.org January 2015 | Volume 6 | Article 2 | 1
Kamiya Inner ear cell therapy
FIGURE 1 | Schematic diagram of the strategy to activate stem cell
homing in the mouse cochlea. 1. Upregulation of homing receptors (CCR2,
CXCR4) in culture dish by the treatment of MCP-1 or SDF-1. The cells with
abundant CCR2 and CXCR4 acquire the higher potentials to be attracted by
MCP-1 and SDF-1 (black arrows). 2. The pretreated cells are injected into the
perilymph via the semicircular canal. 3. MCP-1/SDF-1 secretion from the
target site by pre-treatment with 3-nitropropionic acid (3-NP). 4. Transplanted
cells home to the target site.
spiral ligament after acoustic deafening promoted homing of the
cell to the cochlea (Tan et al., 2008).
ACTIVATION OF STEM CELL HOMING FACTORS IN COCHLEA
AND STEM CELLS
To establish an efficient cell therapy for hereditary deafness, we
examined treatments that enhanced stem cell homing factors
in the cochlear tissue and MSC. We examined inner ear MSC
transplantation in CX26 deficient mice, which we developed as
a model of hereditary hearing loss (Kamiya et al., 2014). We
transplanted the MSCs to the lateral semicircular canal after the
induction of stem cell homing factors (SDF-1; MCP-1) in the
host cochlear tissue, and their receptors in transplanted MSCs.
To enhance the invasion by MSCs of the cochlear tissue, we
developed a novel transplant strategy by inducing SDF-1/MCP-1
expression in the host cochlear tissue and enhanced the expression
of their receptors, CCR2 and C-X-C chemokine receptor type 4
(CXCR4) in MSCs (Figure 1). With this strategy, we induced effi-
cient invasion of MSCs to the inner ear tissue and differentiation
to form gap junctions with CX26 among transplanted MSCs in
CX26-deficiente mouse inner ear (unpublished observation).
By using newly generated mouse models and a new strategy for
the activation of stem cell homing factors, it may be possible to
establish an efficient inner ear cell therapy for recovering hearing
in hereditary deafness.
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